logo-loader
Oncimmune

Oncimmune CEO details multi-million-pound deal with Russia’s leading drugmaker

Adam Hill, chief executive of Oncimmune Holdings PLC (LON:ONC), talks Proactive London's Andrew Scott through a multi-million-pound deal they've signed which will see its EarlyCDT Lung cancer detection test used by Russia’s leading drugmaker.

R-Pharm now has the exclusive right to use the EarlyCDT Lung in Russia, as well as in Belarus, Kazakhstan, Armenia and Kyrgyzstan, for the next five years.

Quick facts: Oncimmune

Price: 50.5 GBX

Market: AIM
Market Cap: £31.94 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Oncimmune named herein, including the promotion by the Company of Oncimmune in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

New US deal for Oncimmune on the back of mixed results

Oncimmune Holdings PLC (LON:ONC) has inked a new deal with US diagnostics firm Biodesix for its EarlyCDT lung cancer test. CEO Adam Hill tells Proactive London how significant the deal is and lays out his new three year strategic vision for the company, underlining a newly-implemented and...

2 weeks ago

2 min read